Frankfurt
13.11.25 | 08:11
0,898 Euro
+2,98 % +0,026
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Diamyd Medical AB Ser. B Full Year Sales Decline | 1 | RTTNews | ||
| Do | DIAMYD MEDICAL AB: Information about the Annual Report 2024/2025 | 1 | Cision News | ||
| Mi | DIAMYD MEDICAL AB: Diamyd Medical marks World Diabetes Day with expert panel on the future of Type 1 Diabetes treatment | 3 | Cision News | ||
| 08.10. | Diamyd Medical AB Ser. B Q4 Loss Widens | - | RTTNews | ||
| 08.10. | DIAMYD MEDICAL AB: Year-End Report 24/25 | 1 | Cision News | ||
| 08.10. | Diamyd Medical AB (publ): Year-End Report 24/25 | 189 | GlobeNewswire (Europe) | September 2024 - August 2025, Diamyd Medical AB (publ), Fiscal year 2024/2025
Precision Medicine for Type 1 Diabetes
Aiming for Accelerated Market Approval
Diamyd Medical develops a proprietary platform... ► Artikel lesen | |
| 03.10. | DIAMYD MEDICAL AB: Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 1 | Cision News | ||
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 03.10. | Diamyd Medical AB (publ): Hong Kong grants precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 108 | GlobeNewswire (Europe) | Diamyd Medical has been granted a patent in Hong Kong protecting the use of insulin-based antigens to treat individuals with type 1 diabetes carrying the HLA DR4-DQ8 genetic marker. The patent is valid... ► Artikel lesen | |
| 11.09. | DIAMYD MEDICAL AB: New analysis to be presented at EASD supports potential of Diamyd to delay the progression of Stage 3 Type 1 Diabetes | 2 | Cision News | ||
| 10.09. | DIAMYD MEDICAL AB: Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 2 | Cision News | ||
| 10.09. | Diamyd Medical AB (publ): Eurasia to grant precision medicine patent to Diamyd Medical for insulin antigen treatment in type 1 diabetes | 117 | GlobeNewswire (Europe) | The Eurasian Patent Office has informed Diamyd Medical that the patent application protecting the use of insulin-based antigens for the treatment of individuals with type 1 diabetes carrying the HLA... ► Artikel lesen | |
| 05.09. | DIAMYD MEDICAL AB: ASSET partnership, coordinated by Diamyd Medical, organizes 2[nd] annual Type 1 Diabetes screening conference | 1 | Cision News | ||
| 22.07. | DIAMYD MEDICAL AB: Diamyd Medical releases the full video recording from a panel discussion at the ADA meeting in June | 1 | Cision News | ||
| 25.06. | DIAMYD MEDICAL AB: Quarterly Report 3 24/25 | 2 | Cision News | ||
| 25.06. | Diamyd Medical AB (publ): Quarterly Report 3 24/25 | 183 | GlobeNewswire (Europe) | Precision Medicine for Autoimmune Diabetes
Aiming for Accelerated Market Approval
Autoimmune or Type-1 Diabetes (T1D) is a progressive disease, diagnosed as at least two antibodies to the insulin producing... ► Artikel lesen | |
| 16.06. | DIAMYD MEDICAL AB: Diamyd Medical to participate in two key US diabetes events | 11 | Cision News | ||
| 19.05. | Diamyd Medical AB (publ): Diamyd Medical appoints Niklas Axelsson as CFO | 169 | GlobeNewswire (Europe) | Niklas Axelsson has been appointed CFO of Diamyd Medical. He will assume his position in August and will also join the management team. Niklas Axelsson brings more than 25 years of experience across... ► Artikel lesen | |
| 25.04. | Diamyd Medical AB (publ): Diamyd Medical's pivotal Phase 3 Type 1 Diabetes trial clears second-to-last safety review ahead of early readout in March 2026 | 199 | GlobeNewswire (Europe) | The independent Data Safety Monitoring Board (DSMB) has completed its fifth scheduled safety review of Diamyd Medical's registrational Phase 3 trial, DIAGNODE-3, evaluating the precision medicine immunotherapy... ► Artikel lesen | |
| 21.04. | Diamyd Medical AB: Diamyd Medical highlights opportunity in Type 1 Diabetes prevention, adult-onset market, and upcoming Phase 3 readout | 356 | PR Newswire | STOCKHOLM, April 21, 2025 /PRNewswire/ -- In a recent investor interview, Diamyd Medical Board Member Professor Mark Atkinson and CEO Ulf Hannelius shared key insights into the Company's... ► Artikel lesen | |
| 15.04. | Diamyd Medical AB (publ): Australia grants Diamyd Medical patent for novel antigen combination in autoimmune diabetes treatment | 190 | GlobeNewswire (Europe) | The Australian Patent Office has granted a patent protecting a novel immunotherapeutic composition developed by Diamyd Medical for use in the treatment and prevention of autoimmune diabetes. The patent... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 42,560 | -0,82 % | Übernahmekampf bei Novo Nordisk und Pfizer! BioNxt Solutions das nächste Ziel? | Wer übernimmt Metsera? Darüber streiten derzeit Novo Nordisk und Pfizer. Beide Pharmariesen wollen sich mit der Übernahme den Zugriff auf eine neue Generation von Stoffwechseltherapien sichern, die... ► Artikel lesen | |
| PFIZER | 22,130 | -0,81 % | Pfizer's former R&D chief Dolsten pulls out of Novo Nordisk board race | ||
| ABBVIE | 201,00 | -0,25 % | Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders | PARMA, Italy, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Chiesi Group today announced it has entered into an exclusive license agreement with Aliada Therapeutics, a wholly owned subsidiary of AbbVie, to advance... ► Artikel lesen | |
| ABBOTT LABORATORIES | 110,74 | -0,36 % | Die Mehrheit1 privat versicherter Menschen mit Diabetes erhält verbesserten Zugang zum FreeStyle Libre Messsystem von Abbott - auch bei Typ-2-Diabetes außerhalb der intensivierten Insulintherapie* | Wiesbaden (ots) - Für Menschen mit Typ-1- oder Typ-2-Diabetes und intensivierter Insulintherapie (ICT) ist die kontinuierliche Glukosemessung (CGM) in der Versorgung etabliert2,3. Dank Kooperationen... ► Artikel lesen | |
| ZOETIS | 104,44 | -0,21 % | ZOETIS INC steht still - ich rieche Bewegung! | ||
| AXSOME THERAPEUTICS | 117,55 | -3,37 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy | Axsome obtains exclusive global rights to AZD7325, a novel oral selective GABAA a2,3 receptor positive allosteric modulator Deepens Axsome's broad and innovative neuroscience portfolio with a synergistic... ► Artikel lesen | |
| DAIICHI SANKYO | 18,700 | -4,23 % | General Proximity Announces Multi-Target Collaboration with Daiichi Sankyo to Discover and Advance Novel Oncology Therapeutics Using OmniTAC Platform | - The collaboration will leverage General Proximity's OmniTAC platform to identify and advance next generation induced proximity agents for high value oncology targets. - Induced proximity... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,680 | +0,13 % | Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y | ||
| TRULIEVE CANNABIS | 5,550 | -7,19 % | Trulieve Cannabis just got a massive price target raise from this analyst | ||
| ACADIA PHARMACEUTICALS | 20,880 | +0,24 % | RBC senkt Kursziel für Acadia Pharmaceuticals wegen schwacher Medicaid-Nachfrage | ||
| BRIDGEBIO PHARMA | 56,12 | -1,82 % | BridgeBio Pharma, Inc.: Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations | - Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated:59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared... ► Artikel lesen | |
| TG THERAPEUTICS | 26,985 | +0,80 % | TG Therapeutics: Optimistischer Ausblick für MS-Medikament Briumvi auf dem TD Cowen Summit | ||
| CNBX PHARMACEUTICALS | - | - | CNBX Pharmaceuticals Inc. - 10-Q, Quarterly Report | ||
| AURINIA PHARMACEUTICALS | 13,155 | -1,86 % | Jefferies upgrades Aurinia Pharmaceuticals stock to Buy on strong Lupkynis sales | ||
| CAMURUS | 56,70 | +0,71 % | AKTIONÄR-Tipp Camurus: Gamechanger im Adipositas-Markt? Kurssprung! | Der Adipositas-Markt zählt innerhalb der Biopharma-Branche weiterhin zu den heißesten Bereichen - nicht zuletzt durch den Bieterkampf zwischen Pfizer und Novo Nordisk um Metsera. Unlängst verschiebt... ► Artikel lesen |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +2,98 % bei einem Aktienkurs von 0,898 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.